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Psychosis is a significant psychiatric disorder in Parkinson disease (PD), with a long-term 
cumulative prevalence of 60%(1).  Approximately 50% of patients with PD psychosis (PDP) are 
treated with an antipsychotic (AP), most commonly quetiapine(2).  Large-scale 
pharmacoepidemiological research in PD demonstrated that AP treatment is associated with 
increased mortality(3) and morbidity(4), but little is known about mortality and morbidity at the 
individual patient level.  Using administrative and clinical record data from six specialty PD 
centers, we assessed correlates of negative outcomes in patients initiating quetiapine.  
 
The study included 261 patients receiving care at a US Veterans Affairs PD center (PADRECC), 
with idiopathic PD, stable physical health, and a new quetiapine prescription(3, 4).  Two raters 
abstracted data from medical notes in the year preceding quetiapine treatment.  Administrative 
data included a diagnosis of depression, use of non-psychiatric medications, and medical 
comorbidity. 
 
We utilized a combined physical morbidity-mortality outcome of a VA ER visit, VA 
hospitalization, or death as a “negative” outcome.  Comparisons between those with and without 
a negative outcome during the 180-days of follow-up were made using the χ2 test or two-sample 
t-test.  A Cox regression model was used to model time to first occurrence of a negative 
outcome, adding clinical measures individually after adjusting for administrative data-based 
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measures.  Adjusted hazard ratios (AHR) are reported for clinical measures, and analyses were 
repeated after multiply imputing the missing measures.       
 
The study cohort of 261 newly-treated quetiapine patients was elderly (mean age =75 years), 
nearly all male (99.2%), diverse in terms of PD severity based on H&Y stage, and with high 
rates of cognitive (80%) and gait (90%) impairment, indicating a vulnerable population.  
Prevalence of a negative outcome was high, with 104 (39.8%) individuals having at least one 
over the 180-day follow-up period.  This included (groups not mutually exclusive) 18 (17.3%) 
individuals who died, 88 (33.7%) with an ER visit, and 57 (21.8%) who were hospitalized.   
 
In bivariate analyses a comorbid depression diagnosis and greater medical co-morbidity were 
correlates of a negative outcome.  Of the chart abstraction-based measures, PD severity, 
decreased mobility, and orthostasis were predictive of a negative outcome (Table 1).  In the Cox 
models greater PD severity (AHR=3.37; 95% CI=2.14, 5.30), impaired balance (AHR=2.14; 
95%CI=1.18, 3.86) and gait impairment (AHR=2.02; 95% CI=1.19, 3.42) predicted a negative 
outcome (Supplementary Table 1).  When the analyses were repeated using 25 multiply 
imputed datasets, positive association for gait and balance impairment remained significant.    
 
The clinical correlates of a negative outcome with quetiapine treatment fit into three categories: 
severe disease, autonomic dysfunction and co-morbidity.  APs can worsen parkinsonism, and the 
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association between more severe disease and a negative outcome might be mediated by injuries.  
Orthostasis is common in PD and a side-effect of low-potency APs.  Co-morbid medical 
conditions and depression might be associated with a risk of negative outcomes through 
interactions with neurobiological and psychological factors or concomitant medications.  
 
Study limitations include no matched comparison of non-treated patients to determine if 
predictors of a negative outcome are different for quetiapine-treated versus non-treated patients; 
examination of quetiapine only; examination of male veterans only; retrospective study design 
with some missing chart-abstracted variables; and lack of data on the cause of negative 
outcomes, PD or psychosis duration, and dose or duration of quetiapine treatment, or use of other 
APs, during the observation period.  These data would allow further understanding of the 
potential role of these variables in negative outcomes. 
 
Initiation of AP for PDP needs to be informed by the risks and benefits.  Future prospective 
controlled research should compare rates and predictors of negative outcomes in patients treated 
with quetiapine and other APs, and a matched comparison group.  
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Table 1: Demographic and clinical predictors of negative outcome in PD patients treated 
with quetiapine 
 
   Negative Outcome  
  Total (N=261) Yes (N=104) No (N=157) p value2  
N % N % N %   
Administrative data-based variables            
 







Female 2 0.8% 1 1.0% 1 0.6% 0.77 
Race 
       
   White 206 78.9% 85 81.7% 121 77.1% 0.29 
   Black 19 7.3% 6 5.8% 13 8.3% 
 
   Other 4 1.5% 3 2.9% 1 0.6% 
 
   Unknown 32 12.3% 10 9.6% 22 14.0% 
 
Married 195 74.7% 74 71.2% 121 77.1% 0.28 
New non-psych meds in past 14 days  14 5.4% 5 4.8% 9 5.7% 0.75 
Within one year prior to index 
       
   Depression  74 28.4% 38 36.5% 36 22.9% 0.02 
   Charlson=0 161 61.7% 49 47.1% 112 71.3% <0.001 
      Charlson=1 39 14.9% 24 23.1% 15 9.6% 
 
      Charlson>1 61 23.4% 31 29.8% 30 19.1% 
 
   Inpatient days=0 227 87.0% 85 81.7% 142 90.4% 0.09 
      Inpatient days=1-5 14 5.4% 9 8.7% 5 3.2% 
 
      Inpatient days>5 20 7.7% 10 9.6% 10 6.4% 
 
   Nursing homes days=0 258 98.9% 102 98.1% 156 99.4% 0.75 




       
Hoehn & Yahr stage (3-5 vs. 0-2.5) 70 61.4% 35 81.4% 35 49.3% 0.001 
   Missing1 147 56.3% 61 58.7% 86 54.8% 
 
Gait impairment  231 89.9% 96 94.1% 135 87.1% 0.09 
   Missing1 4 1.5% 2 1.9% 2 1.3% 
 
Cognitive impairment  189 79.1% 76 79.2% 113 79.0% 1.00 
   Missing1 22 8.4% 8 7.7% 14 8.9% 
 
Swallowing difficulty 87 46.8% 34 47.2% 53 46.5% 1.00 
   Missing1 75 28.7% 32 30.8% 43 27.4% 
 
Falls by history 165 72.1% 69 76.7% 96 69.1% 0.23 
   Missing1 32 12.3% 14 13.5% 18 11.5% 
 
Mobility level 
      
0.03 
   Without assistance: 0 61 27.4% 17 18.7% 44 33.3%  
   Walker or Cane: 1 118 52.9% 51 56.0% 67 50.8% 
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   Wheelchair: 2 43 19.3% 22 24.2% 21 15.9% 
 
   Bedridden: 3 1 0.4% 1 1.1% 0 0.0% 
 
   Missing1 38 14.6% 13 12.5% 25 15.9% 
 
Balance impairment 214 87.0% 93 92.1% 121 83.4% 0.06 
   Missing1 15 5.7% 3 2.9% 12 7.6% 
 
Orthostasis present 84 45.4% 39 55.7% 45 39.1% 0.03 
   Missing1 76 29.1% 34 32.7% 42 26.8%   
 
Note: Some patients had more than 1 negative outcome.  Among 104 quetiapine users with negative 
outcomes, 84.6% had ER, 54.8% had IP, 17.3% died in follow-up.  
1 Percentages are calculated out of total N=261, N=104 with negative outcome and N=157 without 
negative outcome. 
2 From comparing means for age using two group t-test and comparing percentages with the 
characteristics for other variables using chi-square test between those with vs. without negative outcome. 
For chart-based variables, comparisons excluded those with missing information on the characteristics.  
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Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement 
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for 
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder 
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints i  the 
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article, 
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and 
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at 
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint o  replace it with the 
published version of the Contribution.    
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version 
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate 
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms 
apply if the Contributor receives or received funding from these agencies. The details of those relationships, 
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/ 
funderstatement.  
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research 
Councils UK (RCUK) and Wellcome Trust require deposit f the Accepted Version in a public repository 
after an embargo period.   Details of funding arrangements are set out at the following website: 
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the 
production editor for the journal at MDSprod@wiley.com if you have additional funding requirements. 
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expir d, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for 
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for 
research funded by ESRC or AHRC. 
5.  Additional Terms for Certain Institutions.   Wiley has arrangements with certain educational 
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo 
period.    Details of such arrangements are set out at the following website: 
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable. 
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See th  
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html. 
This article is protected by copyright. All rights reserved.
D. CONTRIBUTIONS OWNED BY EMPLOYER  
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
 E. GOVERNMENT CONTRACTS  
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for o ficial 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS  
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or cntain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examin tion by the editors or their assignees. 
G. FINANCIAL DISCLOSURES 
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT 
In the event that the Contribution includes, discloes or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
This article is protected by copyright. All rights reserved.
I. ACKNOWLEDGEMENTS 
The Contributor should obtain written permission from all individuals named in the acknowledgement since 
readers may infer their endorsement of data and conclusions.  The Contributor certifies that all individuals 
named in the acknowledgement section have provided written permission to be named. 
J. MISCELLANEOUS 
This Agreement may be amended or modified only in a writing executed by both parties.  The waiver or 
failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other 
limitation of any other right or any future right.  This Agreement shall inure to the benefit of, and shall be 
binding upon, the parties, their respective successors and permitted assigns.  This Agreement may be 
executed in two (2) or more counterparts, each of which shall be an original and all of which taken together 
shall constitute one and the same agreement.  Executed copies of this Agreement may be delivered by 
facsimile transmission, pdf/email or other comparable electronic means.  If for any reason any provision of this 
Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the 
validity, legality and enforceability of the remainder of this Agreement shall not be affected and such 
provision shall be deemed modified to the minimum extent necessary to make such provision consistent with 
applicable law and, in its modified form, such provision shall then be enforceable and enforced.  The parties 
agree to do such further acts and to execute and deliver such additional agreements and instruments from 
time to time as either may at any time reasonably request in order to assure and confirm unto such requesting 
party the rights, powers and remedies conferred in the Agreement.  This Agreement, including any exhibits 
attached hereto, contains the entire agreement and understanding of the parties with respect to the subject 
matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and 
oral, relating thereto. 
All Contributors must sign below.  Contributors must check one box except that NIH grantees should 
check both Contributor-owned work and the NIH grantee box.  If your Contribution was written 
during the course of employment, your employer must also sign where indicated. 
Please send your original completed and signed forms by fax or email a scanned copy to the Journal 
production editor.  For production editor contact details please visit the Journal’s online author guidelines.  
Do not send in hard copies of these forms. 
 
[ ] Contributor-owned work         
     Contributor’s signature    Date 
 
             
     Type or print name and title 
 
 
             
     Co-Contributor’s signature   Date 
 
             
     Type or print name and title 
     
 
Jayne R. Wilkinson, MD, MSCE
5/22/20x
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[ ] Company/Institution-owned         
   Work (made-for-hire in the  Company or Institution (Employer-for-Hire) Date 
   Course of employment) 
 
             
     Authorized signature of Employer  Date 
 
 
              
     Contributor’s signature    Date 
 
      
           
     Type or print name and title 
 
 





 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
 
[ ] U.K. Government work (Crown Copyright)   
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
 
x
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The Contributor has received financial and material support for this research and work regardless of date 
from the following sources: 
Name:        
Address:       
Type of support:       
This material will be printed with the published article. 
 
 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
 
Name:        
Address:       
Type of support:       
This material will be posted on the journal website and may be printed at the Editors’ discretion. 
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COPYRIGHT TRANSFER AGREEMENT 
 (the “Contribution”) 
Date:  05/22/2020
Contributor name:   
Contributor address:   
Manuscript number:   MDS-20-0642.R1
Re: Manuscript entitled: Clinical follow up of PD  
for publication in: Movement Disorders (the “Journal”) 
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
A. COPYRIGHT
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to
reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the
original form submitted to the Journal prior to the peer review process, solely to colleagues within the
Contributor’s nonprofit organization or educational institution.  The Contributor shall make no more than
100 printed copies of the preprints in any calendar year.   Such preprints may be posted as electronic files on
the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit
organization or educational institution, or on a secure external website at the Contributor’s nonprofit
organization or educational institution, provided that access is limited to employees and/or students at
Contributor’s non-profit organization or educational institution.    Contributor shall not charge a fee for any
with newly prescribed
quetiapine  
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preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any
systematic external distribution (e.g., posting on a listserve, public website, database connected to a public 
access server, or automated delivery system).  The license grant in this Section does not apply to for-profit 
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing 
by the Owner.  The rights granted to Contributor under this Section C do not include reproduction, 
distribution or any other use of rating scales, videos or other audiovisual materials associated with the 
Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement 
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for 
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder 
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints i  the 
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article, 
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and 
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at 
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint o  replace it with the 
published version of the Contribution.    
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version 
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate 
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms 
apply if the Contributor receives or received funding from these agencies. The details of those relationships, 
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/ 
funderstatement.  
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research 
Councils UK (RCUK) and Wellcome Trust require deposit f the Accepted Version in a public repository 
after an embargo period.   Details of funding arrangements are set out at the following website: 
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the 
production editor for the journal at MDSprod@wiley.com if you have additional funding requirements. 
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expir d, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for 
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for 
research funded by ESRC or AHRC. 
5.  Additional Terms for Certain Institutions.   Wiley has arrangements with certain educational 
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo 
period.    Details of such arrangements are set out at the following website: 
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable. 
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See th  
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html. 
This article is protected by copyright. All rights reserved.
D. CONTRIBUTIONS OWNED BY EMPLOYER  
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
 E. GOVERNMENT CONTRACTS  
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for o ficial 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS  
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or cntain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examin tion by the editors or their assignees. 
G. FINANCIAL DISCLOSURES 
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT 
In the event that the Contribution includes, discloes or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
This article is protected by copyright. All rights reserved.
I. ACKNOWLEDGEMENTS 
The Contributor should obtain written permission from all individuals named in the acknowledgement since 
readers may infer their endorsement of data and conclusions.  The Contributor certifies that all indivi uals 
named in the acknowledgement section have provided written permission to be named. 
J. MISCELLANEOUS 
This Agreement may be amended or modified only in a writing executed by both parties.  The waiver or 
failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other 
limitation of any other right or any future right.  This Agreement shall inure to the benefit of, and shall be 
binding upon, the parties, their respective successors and permitted assigns.  This Agreement may be 
executed in two (2) or more counterparts, each of which shall be an original and all of which taken together 
shall constitute one and the same agreement.  Executed opies of this Agreement may be delivered by 
facsimile transmission, pdf/email or other comparable electronic means.  If for any reason any provisin of this 
Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the 
validity, legality and enforceability of the remainder of this Agreement shall not be affected and such 
provision shall be deemed modified to the minimum extent necessary to make such provision consistent with 
applicable law and, in its modified form, such provision shall then be enforceable and enforced.  The parties 
agree to do such further acts and to execute and deliver such additional agreements and instruments from 
time to time as either may at any time reasonably request in order to assure and confirm unto such requesting 
party the rights, powers and remedies conferred in the Agreement.  This Agreement, including any exhibits 
attached hereto, contains the entire agreement and understanding of the parties with respect to the subject 
matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and 
oral, relating thereto. 
All Contributors must sign below.  Contributors must check one box except that NIH grantees should 
check both Contributor-owned work and the NIH grantee box.  If your Contribution was written 
during the course of employment, your employer must also sign where indicated. 
Please send your original completed and signed forms by fax or email a scanned copy to the Journal 
production editor.  For production editor contact de ails please visit the Journal’s online author guidelines.  
Do not send in hard copies of these forms. 
 
[ ] Contributor-owned work         
     Contributor’s signature    Date 
 
             
     Type or print name and title 
 
 
             
     Co-Contributor’s signature   Date 
 
             
     Type or print name and title 
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[ ] Company/Institution-owned         
   Work (made-for-hire in the  Company or Institution (Employer-for-Hire) Date 
   Course of employment) 
 
             
     Authorized signature of Employer  Date 
 
 
              
     Contributor’s signature    Date 
 
      
           
     Type or print name and title 
 
 





 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
 
[ ] U.K. Government work (Crown Copyright)   
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work 
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
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The Contributor has received financial and material support for this research and work regardless of date
from the following sources: 
Name:        
Address:       
Type of support:       
This material will be printed with the published article. 
 
 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory b ards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
 
Name:        
Address:       
Type of support:       
This material will be posted on the journal website and may be printed at the Editors’ discretion. 
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COPYRIGHT TRANSFER AGREEMENT 
Date: 05/22/2020 
Contributor name: Helen Kales 
Contributor address: __________________ _ 
Manuscript number: _,.MD= S__,-2,,_,0'--0""'6"-4=2=.R=l"-------------
Re: Manuscript entitled: Clinical follow up of PD with newly prescribed (the "Contribution") 
quetiapine 
for publication in: Movement Disorders (the "Journal") 
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
"Owner") 
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
A. COPYRIGHT
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so. 
B. RETAINED RIGHTS
Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution. This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A. 
C. PERMITTED USES BY CONTRIBUTOR
1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to
reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the
original form submitted to the Journal prior to the peer review process, solely to colleagues within the
Contributor's nonprofit organization or educational institution. The Contributor shall make no more than
100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on
the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit
organization or educational institution, or on a secure external website at the Contributor's nonprofit
organization or educational institution, provided that access is limited to employees and/or students at
Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any
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Re: Manuscript entitled:  (the “Contribution”) 
for publication in:  Movement Disorders (the “Journal”) 
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
A. COPYRIGHT
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to
reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the
original form submitted to the Journal prior to the peer review process, solely to colleagues within the
Contributor’s nonprofit organization or educational institution.  The Contributor shall make no more than
100 printed copies of the preprints in any calendar year.   Such preprints may be posted as electronic files on
the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit
organization or educational institution, or on a secure external website at the Contributor’s nonprofit
organization or educational institution, provided that access is limited to employees and/or students at
Contributor’s non-profit organization or educational institution.    Contributor shall not charge a fee for any
MDS-20-0642.R1
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preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any 
systematic external distribution (e.g., posting on a listserve, public website, database connected to a public 
access server, or automated delivery system).  The license grant in this Section does not apply to for-profit 
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing 
by the Owner.  The rights granted to Contributor under this Section C do not include reproduction, 
distribution or any other use of rating scales, videos or other audiovisual materials associated with the 
Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints in the
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article,
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint or replace it with the
published version of the Contribution.
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms
apply if the Contributor receives or received funding from these agencies. The details of those relationships,
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/
funderstatement.
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research
Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository
after an embargo period.   Details of funding arrangements are set out at the following website:
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the
production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expired, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for
research funded by ESRC or AHRC. 
5. Additional Terms for Certain Institutions.   Wiley has arrangements with certain educational
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo
period.    Details of such arrangements are set out at the following website:
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable.
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See the 
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html. 
This article is protected by copyright. All rights reserved.
D. CONTRIBUTIONS OWNED BY EMPLOYER
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
E. GOVERNMENT CONTRACTS
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from 
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examination by the editors or their assignees. 
G. FINANCIAL DISCLOSURES
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT
In the event that the Contribution includes, discloses or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
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I. ACKNOWLEDGEMENTS
The Contributor should obtain written permission from all individuals named in the acknowledgement since 
readers may infer their endorsement of data and conclusions.  The Contributor certifies that all individuals 
named in the acknowledgement section have provided written permission to be named. 
J. MISCELLANEOUS
This Agreement may be amended or modified only in a writing executed by both parties.  The waiver or 
failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other 
limitation of any other right or any future right.  This Agreement shall inure to the benefit of, and shall be 
binding upon, the parties, their respective successors and permitted assigns.  This Agreement may be 
executed in two (2) or more counterparts, each of which shall be an original and all of which taken together 
shall constitute one and the same agreement.  Executed copies of this Agreement may be delivered by 
facsimile transmission, pdf/email or other comparable electronic means.  If for any reason any provision of this 
Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the 
validity, legality and enforceability of the remainder of this Agreement shall not be affected and such 
provision shall be deemed modified to the minimum extent necessary to make such provision consistent with 
applicable law and, in its modified form, such provision shall then be enforceable and enforced.  The parties 
agree to do such further acts and to execute and deliver such additional agreements and instruments from 
time to time as either may at any time reasonably request in order to assure and confirm unto such requesting 
party the rights, powers and remedies conferred in the Agreement.  This Agreement, including any exhibits 
attached hereto, contains the entire agreement and understanding of the parties with respect to the subject 
matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and 
oral, relating thereto. 
All Contributors must sign below.  Contributors must check one box except that NIH grantees should 
check both Contributor-owned work and the NIH grantee box.  If your Contribution was written 
during the course of employment, your employer must also sign where indicated. 
Please send your original completed and signed forms by fax or email a scanned copy to the Journal 
production editor.  For production editor contact details please visit the Journal’s online author guidelines. 
Do not send in hard copies of these forms. 
[ ] Contributor-owned work 
Contributor’s signature Date 
Type or print name and title 
Co-Contributor’s signature Date 




This article is protected by copyright. All rights reserved.
[ ] Company/Institution-owned 
 Work (made-for-hire in the Company or Institution (Employer-for-Hire) Date 
 Course of employment) 
Authorized signature of Employer Date 
Contributor’s signature Date 
Type or print name and title 
ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY 
 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
[ ] U.K. Government work (Crown Copyright)   
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
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Exhibit A  
Financial Disclosure 
Address: 
Type of support:   
This material wil l be printed with the published article. 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
Name:   Daniel Weintraub, MD
Address:   3615 Chestnut Street RM 330  
Type of support:   See Below
This material wil l be posted on the journal website and may be printed at the Editors’ discretion. 
ATTACH ADDITIONAL INFORMATION AS NECESSARY 
The Contributor has received financial and material support for this research and work regardless of date 
from the following sources: 
Name:    
Research Funding or Support : Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Therapeutic 
Research Initiative (ATRI), Alzheimer's Disease Cooperative Study (ADCS), the International Parkinson and 
Movement Disorder Society (IPMDS), and National Institute on Aging (NIA)
Honoraria: Acadia, Aptinyx, Biogen, CHDI Foundation, Clintrex LLC, Eisai, Enterin, F. Hoffman-La Roche Ltd, 
Ferring, Janssen, Otsuka, Promentis, Sage, Signant Health, Sunovion, and Takeda
License Fee Payments: University of Pennsylvania for the QUIP and QUIP-RS
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COPYRIGHT TRANSFER AGREEMENT 
 (the “Contribution”) 
Date:  05/22/2020
Contributor name:   
Contributor address:   
Manuscript number:   MDS-20-0642.R1
Re: Manuscript entitled: Clinical follow up of PD  
for publication in: Movement Disorders (the “Journal”) 
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
A. COPYRIGHT
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to
reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the
original form submitted to the Journal prior to the peer review process, solely to colleagues within the
Contributor’s nonprofit organization or educational institution.  The Contributor shall make no more than
100 printed copies of the preprints in any calendar year.   Such preprints may be posted as electronic files on
the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit
organization or educational institution, or on a secure external website at the Contributor’s nonprofit
organization or educational institution, provided that access is limited to employees and/or students at
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preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any
systematic external distribution (e.g., posting on a listserve, public website, database connected to a public 
access server, or automated delivery system).  The license grant in this Section does not apply to for-profit 
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing 
by the Owner.  The rights granted to Contributor under this Section C do not include reproduction, 
distribution or any other use of rating scales, videos or other audiovisual materials associated with the 
Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement 
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for 
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder 
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints i  the 
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article, 
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and 
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at 
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint o  replace it with the 
published version of the Contribution.    
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version 
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate 
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms 
apply if the Contributor receives or received funding from these agencies. The details of those relationships, 
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/ 
funderstatement.  
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research 
Councils UK (RCUK) and Wellcome Trust require deposit f the Accepted Version in a public repository 
after an embargo period.   Details of funding arrangements are set out at the following website: 
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the 
production editor for the journal at MDSprod@wiley.com if you have additional funding requirements. 
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expir d, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for 
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for 
research funded by ESRC or AHRC. 
5.  Additional Terms for Certain Institutions.   Wiley has arrangements with certain educational 
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo 
period.    Details of such arrangements are set out at the following website: 
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable. 
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See th  
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html. 
This article is protected by copyright. All rights reserved.
D. CONTRIBUTIONS OWNED BY EMPLOYER  
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
 E. GOVERNMENT CONTRACTS  
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for o ficial 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS  
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or cntain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examin tion by the editors or their assignees. 
G. FINANCIAL DISCLOSURES 
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT 
In the event that the Contribution includes, discloes or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
This article is protected by copyright. All rights reserved.
I. ACKNOWLEDGEMENTS 
The Contributor should obtain written permission from all individuals named in the acknowledgement since 
readers may infer their endorsement of data and conclusions.  The Contributor certifies that all individuals 
named in the acknowledgement section have provided written permission to be named. 
J. MISCELLANEOUS 
This Agreement may be amended or modified only in a writing executed by both parties.  The waiver or 
failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other 
limitation of any other right or any future right.  This Agreement shall inure to the benefit of, and shall be 
binding upon, the parties, their respective successors and permitted assigns.  This Agreement may be 
executed in two (2) or more counterparts, each of which shall be an original and all of which taken together 
shall constitute one and the same agreement.  Executed copies of this Agreement may be delivered by 
facsimile transmission, pdf/email or other comparable electronic means.  If for any reason any provision of this 
Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the 
validity, legality and enforceability of the remainder of this Agreement shall not be affected and such 
provision shall be deemed modified to the minimum extent necessary to make such provision consistent with 
applicable law and, in its modified form, such provision shall then be enforceable and enforced.  The parties 
agree to do such further acts and to execute and deliver such additional agreements and instruments from 
time to time as either may at any time reasonably request in order to assure and confirm unto such requesting 
party the rights, powers and remedies conferred in the Agreement.  This Agreement, including any exhibits 
attached hereto, contains the entire agreement and understanding of the parties with respect to the subject 
matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and 
oral, relating thereto. 
All Contributors must sign below.  Contributors must check one box except that NIH grantees should 
check both Contributor-owned work and the NIH grantee box.  If your Contribution was written 
during the course of employment, your employer must also sign where indicated. 
Please send your original completed and signed forms by fax or email a scanned copy to the Journal 
production editor.  For production editor contact details please visit the Journal’s online author guidelines.  
Do not send in hard copies of these forms. 
 
[ ] Contributor-owned work         
     Contributor’s signature    Date 
 
             
     Type or print name and title 
 
 
             
     Co-Contributor’s signature   Date 
 
             
     Type or print name and title 
     
 
x May 22, 2020
Connie Marras MD, PhD
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[ ] Company/Institution-owned         
   Work (made-for-hire in the  Company or Institution (Employer-for-Hire) Date 
   Course of employment) 
 
             
     Authorized signature of Employer  Date 
 
 
              
     Contributor’s signature    Date 
 
      
           
     Type or print name and title 
 
 





 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
 
[ ] U.K. Government work (Crown Copyright)   
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work 
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
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The Contributor has received financial and material support for this research and work regardless of date 
from the following sources: 
Name:        
Address:       
Type of support:       
This material will be printed with the published article. 
 
 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
 
Name:        
Address:       
Type of support:       
This material will be posted on the journal website and may be printed at the Editors’ discretion. 
 
 




Dr. Marras has received research grants from The Michael J Fox Foundation, 
Canadian Institutes of Health Research, Parkinson’s Foundation (US), 
National Institutes of Health (US),  International Parkinson and Movement Disorders Society. 
She is a consultant for Grey Matter Technologies and receives financial compensation as a 
steering committee member from the Michael J Fox Foundation.
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COPYRIGHT TRANSFER AGREEMENT 
 (the “Contribution”) 
Date:   05/22/2020
Contributor name:   Eugenia Mamikonyan  
Contributor address:   3615 Chestnut St. RM 331
Manuscript number:   MDS-20-0642.R1
Re: Manuscript entitled: Clinical follow up of PD  
for publication in: Movement Disorders (the “Journal”) 
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s): 
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
A. COPYRIGHT
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to
reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the
original form submitted to the Journal prior to the peer review process, solely to colleagues within the
Contributor’s nonprofit organization or educational institution.  The Contributor shall make no more than
100 printed copies of the preprints in any calendar year.   Such preprints may be posted as electronic files on
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Table 1: Demographic and clinical predictors of negative outcome in PD patients treated 
with quetiapine 
 
   Negative Outcome  
  Total (N=261) Yes (N=104) No (N=157) p value2  
N % N % N %   
Administrative data-based variables            
 







Female 2 0.8% 1 1.0% 1 0.6% 0.77 
Race 
       
   White 206 78.9% 85 81.7% 121 77.1% 0.29 
   Black 19 7.3% 6 5.8% 13 8.3% 
 
   Other 4 1.5% 3 2.9% 1 0.6% 
 
   Unknown 32 12.3% 10 9.6% 22 14.0% 
 
Married 195 74.7% 74 71.2% 121 77.1% 0.28 
New non-psych meds in past 14 days  14 5.4% 5 4.8% 9 5.7% 0.75 
Within one year prior to index 
       
   Depression  74 28.4% 38 36.5% 36 22.9% 0.02 
   Charlson=0 161 61.7% 49 47.1% 112 71.3% <0.001 
      Charlson=1 39 14.9% 24 23.1% 15 9.6% 
 
      Charlson>1 61 23.4% 31 29.8% 30 19.1% 
 
   Inpatient days=0 227 87.0% 85 81.7% 142 90.4% 0.09 
      Inpatient days=1-5 14 5.4% 9 8.7% 5 3.2% 
 
      Inpatient days>5 20 7.7% 10 9.6% 10 6.4% 
 
   Nursing homes days=0 258 98.9% 102 98.1% 156 99.4% 0.75 




       
Hoehn & Yahr stage (3-5 vs. 0-2.5) 70 61.4% 35 81.4% 35 49.3% 0.001 
   Missing1 147 56.3% 61 58.7% 86 54.8% 
 
Gait impairment  231 89.9% 96 94.1% 135 87.1% 0.09 
   Missing1 4 1.5% 2 1.9% 2 1.3% 
 
Cognitive impairment  189 79.1% 76 79.2% 113 79.0% 1.00 
   Missing1 22 8.4% 8 7.7% 14 8.9% 
 
Swallowing difficulty 87 46.8% 34 47.2% 53 46.5% 1.00 
   Missing1 75 28.7% 32 30.8% 43 27.4% 
 
Falls by history 165 72.1% 69 76.7% 96 69.1% 0.23 
   Missing1 32 12.3% 14 13.5% 18 11.5% 
 
Mobility level 
      
0.03 
   Without assistance: 0 61 27.4% 17 18.7% 44 33.3%  
   Walker or Cane: 1 118 52.9% 51 56.0% 67 50.8% 
   Wheelchair: 2 43 19.3% 22 24.2% 21 15.9% 
 
   Bedridden: 3 1 0.4% 1 1.1% 0 0.0% 
 
   Missing1 38 14.6% 13 12.5% 25 15.9% 
 
Balance impairment 214 87.0% 93 92.1% 121 83.4% 0.06 
   Missing1 15 5.7% 3 2.9% 12 7.6% 
 
Orthostasis present 84 45.4% 39 55.7% 45 39.1% 0.03 
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   Missing1 76 29.1% 34 32.7% 42 26.8%   
 
Note: Some patients had more than 1 negative outcome.  Among 104 quetiapine users with negative 
outcomes, 84.6% had ER, 54.8% had IP, 17.3% died in follow-up.  
1 Percentages are calculated out of total N=261, N=104 with negative outcome and N=157 without 
negative outcome. 
2 From comparing means for age using two group t-test and comparing percentages with the 
characteristics for other variables using chi-square test between those with vs. without negative outcome. 
For chart-based variables, comparisons excluded those with missing information on the characteristics.  
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